Compare NUAI & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUAI | VOGX |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.6M | 482.8M |
| IPO Year | 2024 | 2026 |
| Metric | NUAI | VOGX |
|---|---|---|
| Price | $4.73 | $17.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 7.9M | 100.8K |
| Earning Date | 11-12-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $885,400.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,783.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 66.18 | N/A |
| 52 Week Low | $2.01 | $14.56 |
| 52 Week High | $9.45 | $38.41 |
| Indicator | NUAI | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 34.53 | 36.80 |
| Support Level | $3.89 | N/A |
| Resistance Level | $5.52 | $36.96 |
| Average True Range (ATR) | 0.52 | 3.10 |
| MACD | -0.26 | -1.08 |
| Stochastic Oscillator | 3.89 | 19.55 |
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.